Parabilis Medicines charts $413M IPO to back peptide pipelinenews2026-06-04T13:04:21+00:00June 4th, 2026|Endpoints News|
Alnylam to pay $30M upfront to AI startup Inceptive in RNA R&D dealnews2026-06-03T20:45:47+00:00June 3rd, 2026|Endpoints News|
Regeneron doubles down on CytomX after other pharmas walked awaynews2026-06-03T14:56:16+00:00June 3rd, 2026|Endpoints News|
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseasesnews2026-06-03T11:00:46+00:00June 3rd, 2026|Endpoints News|
Travere pays Everest $112M upfront to grow rare kidney disease pipelinenews2026-06-02T13:55:55+00:00June 2nd, 2026|Endpoints News|
Citing ‘dangerous deals,’ lawmakers propose China restrictionsnews2026-06-02T12:00:58+00:00June 2nd, 2026|Endpoints News|
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listingnews2026-06-01T14:11:13+00:00June 1st, 2026|Endpoints News|
Servier signs $1.55B upfront deal for Edgewise’s muscular dystrophy assetsnews2026-06-01T12:31:49+00:00June 1st, 2026|Endpoints News|
Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfrontnews2026-06-01T10:43:21+00:00June 1st, 2026|Endpoints News|
Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programsnews2026-05-29T10:50:55+00:00May 29th, 2026|Endpoints News|
